Harrow stock highlights 15 ophthalmic studies at AAO

Published on 10/04/2026 at 19:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Harrow stock posted USD 70.66 million in Q2 2026 revenue, while adjusted EPS missed consensus by USD 0.28. The company will present two studies at AAO in October.

HROW, US4158581094, Illustration mit AI erstellt.

Harrow stock (ISIN US4158581094) was last at USD 30.48 on Nasdaq on October 2, 2026 at 4:00 p.m. ET, down 0.42 percent from the prior session. The company is heading into the American Academy of Ophthalmology meeting with 15 scientific presentations across two major eye-care conferences, according to StockTitan on September 30, 2026.

Fifteen studies expand the pipeline story

Harrow has scheduled 13 presentations at the American Academy of Optometry meeting and two at the American Academy of Ophthalmology meeting. The AAO program runs from October 9, 2026, through October 12, 2026, and includes BYQLOVI studies on post-cataract inflammation and pain.

The presentation slate covers VEVYE, VERKAZIA, FLAREX and BYQLOVI, with Phase 3 data, pooled analyses, 52-week safety data, a randomized comparative study and real-world evidence. That mix gives the company a clinical-data angle beyond its next quarterly report.

Revenue grew as losses widened

Harrow generated USD 70.66 million of revenue in Q2 2026, up from USD 63.74 million in Q2 2025, while the company reported a GAAP net loss of USD 17.27 million against net income of USD 5.00 million a year earlier, according to MarketBeat. Adjusted EPS was negative USD 0.46 versus a negative USD 0.18 consensus, a USD 0.28 miss, even as revenue exceeded the USD 70.35 million estimate.

The contrast is the central operating signal: revenue advanced by USD 6.92 million year over year, but the quarterly earnings result moved from profit to loss. For investors, commercial uptake must therefore be weighed against spending, pricing and the cost of expanding the ophthalmic portfolio.

Consensus target stays above the quote

MarketBeat reports a Moderate Buy consensus from 10 analysts, including seven Buy ratings, two Holds and one Sell. The average 12-month price target is USD 66.17, while the October 2 price of USD 30.48 leaves the stock 53.9 percent below that target.

Harrow stock remains below its yearly high

Harrow stock was last at USD 30.48 on Nasdaq on October 2, 2026 at 4:00 p.m. ET, with a 52-week range of USD 28.54 to USD 54.85. Market capitalization stood at USD 1.1 billion and volume reached 566,383 shares on the same date.